Advanced Proteome Therapeutics (Advanced Proteome Therapeutics) Price-to-Owner-Earnings : (As of May. 25, 2024)

Advanced Proteome Therapeutics Price-to-Owner-Earnings Chart

Advanced Proteome Therapeutics Annual Data
	Trend	Jul13	Jul14	Jul15	Jul16	Jul17	Jul18	Jul19	Jul20	Jul21	Jul22
Price-to-Owner-Earnings		Get a 7-Day Free Trial					-	-	-	-	4.46

Advanced Proteome Therapeutics Quarterly Data
	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23
Price-to-Owner-Earnings	Get a 7-Day Free Trial															-	4.46	4.46	-	-

Competitive Comparison of Advanced Proteome Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Advanced Proteome Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Advanced Proteome Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Advanced Proteome Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Advanced Proteome Therapeutics's Price-to-Owner-Earnings falls into.

Advanced Proteome Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Advanced Proteome Therapeutics's Price-to-Owner-Earnings for today is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced Proteome Therapeutics  (OTCPK:APTCF) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.

Advanced Proteome Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Advanced Proteome Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.

Advanced Proteome Therapeutics (Advanced Proteome Therapeutics) Business Description